基于CT的多模态预测模型用于胆囊癌化疗反应:影像与临床生物标志物的整合——一项前瞻性先导研究
这项前瞻性先导研究纳入25例局部晚期或转移性胆囊癌患者,化疗前14天内行双期增强CT,化疗两周期后按RECIST 1.1评估反应。CT-only模型乐观校正后AUC为0.82(95%CI 0.64-0.92),联合模型AUC为0.85(95%CI 0.67-0.95),优于临床-only模型AUC 0.74(95%CI 0.51-0.88)。作者认为基线CT特征联合临床参数可能预测化疗反应,但需外部验证。
要点
- 化疗两周期后按RECIST 1.1评估,11/25例(44%)达部分缓解,14/25例(56%)为非缓解者。
- 联合模型乐观校正后AUC 0.85(95%CI 0.67-0.95),准确率84.0%,敏感度85.7%,特异度81.8%。
- 结石存在与治疗反应相关(单因素p=0.002),较大肝转移灶和高CEA呈不良反应趋势。
核心结论
- 这项初步的假设生成研究提示,将基线CT影像特征与临床参数整合可能预测胆囊癌患者的化疗反应。
研究设计与样本
- 前瞻性先导研究,纳入2023年7月至2025年3月连续25例未经治疗、细胞学/组织学证实的局部晚期或转移性胆囊癌患者,化疗前14天内行双期增强CT,采用逻辑回归(含变量选择与惩罚回归以应对小样本)构建三个探索性预测模型,并以bootstrap验证校正乐观偏倚。
关键影像表现/征象
- 单因素分析中,结石存在(p=0.002)、最大肝转移灶大小(p=0.001)、腹水(p=0.008)为潜在预测因子。
- 年龄(p=0.128)、ALT(p=0.241)、CEA水平(p=0.123)在单因素分析中亦被列为潜在预测因子。
- 结石存在在各模型中均显示为与治疗反应相关的潜在预测因子。
- 较大肝转移灶和CEA升高显示可能与不良反应相关的趋势。
诊断标准与关键数值
- 化疗两周期后按RECIST 1.1评估反应:11/25例(44%)部分缓解,14/25例(56%)为非缓解者(疾病稳定或进展)。
- CT-only模型乐观校正后AUC 0.82(95%CI 0.64-0.92),准确率80.0%,敏感度92.3%,特异度62.5%,Nagelkerke R²=0.272。
- 临床-only模型乐观校正后AUC 0.74(95%CI 0.51-0.88),准确率68.0%,敏感度71.4%,特异度63.6%,Nagelkerke R²=0.424。
- 联合模型乐观校正后AUC 0.85(95%CI 0.67-0.95),准确率84.0%,敏感度85.7%,特异度81.8%,Nagelkerke R²=0.662。
临床应用与阅片要点
- 作者认为基线CT影像特征联合临床参数可能有助于预测胆囊癌化疗反应,但所识别因素需在更大规模多机构队列中外部验证后方可考虑临床实施。
局限性
- 原文明确为小样本(25例)探索性先导研究,采用惩罚回归应对小样本。
- 原文结论指出所识别因素需在更大规模多机构队列中外部验证后方可考虑临床实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Gallbladder carcinoma (GBC) is an aggressive malignancy with poor prognosis, often diagnosed at advanced stages. While chemotherapy forms the cornerstone of treatment for locally advanced and metastatic disease, reliable predictors of response remain elusive. This exploratory pilot study aimed to develop a computed tomography (CT)-based prediction model incorporating clinical and biochemical parameters to identify patients likely to respond to chemotherapy.
METHODS: This prospective study enrolled consecutive treatment-naïve patients with cytologically/histologically proven locally advanced or metastatic GBC scheduled for chemotherapy between July 2023 and March 2025. All patients underwent biphasic contrast-enhanced CT within 14 days prior to chemotherapy initiation. Demographic variables, biochemical parameters, and tumor markers (CA 19 - 9, CEA) were systematically recorded. CT-based response assessment was performed using RECIST 1.1 criteria after two cycles of chemotherapy. Three exploratory prediction models were developed using logistic regression with appropriate variable selection methods and penalized regression to address small sample size.
RESULTS: Of 25 patients (18 females, mean age 50.0 ± 11.6), 11 (44%) achieved partial response while 14 (56%) were non-responders (stable or progressive disease). Univariate analysis identified calculus presence (p = 0.002), largest liver metastasis size (p = 0.001), ascites (p = 0.008), age (p = 0.128), ALT (p = 0.241), and CEA levels (p = 0.123) as potential predictors. After correction for optimism using bootstrap validation, the CT-only model achieved area under the receiver operating characteristic curve (AUC) of 0.82 (95% CI: 0.64-0.92) with 80.0% accuracy, 92.3% sensitivity, and 62.5% specificity (Nagelkerke R²=0.272). The clinical-only model yielded optimism-corrected AUC of 0.74 (95% CI: 0.51-0.88) with 68.0% accuracy, 71.4% sensitivity, and 63.6% specificity (Nagelkerke R²=0.424). The combined model showed better performance with optimism-corrected AUC of 0.85 (95% CI: 0.67-0.95), 84.0% accuracy, 85.7% sensitivity, 81.8% specificity, and highest explained variance (Nagelkerke R²=0.662). Gallstone presence emerged as a potential predictor associated with treatment response across models, while larger liver lesions and elevated CEA showed trends that may be associated with poor response.
CONCLUSIONS: This preliminary hypothesis-generating study suggests that integration of baseline CT imaging features with clinical parameters may potentially allow prediction of chemotherapy response in GBC patients. The identified factors require external validation in larger multi-institutional cohorts before clinical implementation can be considered.
引用
- Sharma K, Gupta P, Gulati A, et al. CT-based multimodal prediction model for chemotherapy response in gallbladder cancer: integration of imaging and clinical biomarkers-a prospective pilot study. Abdom Radiol (NY). 2025. PMID: 41051493. doi:10.1007/s00261-025-05209-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。